Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).
M. Kittaneh
No relevant relationships to disclose
A. J. Montero
No relevant relationships to disclose
K. Kovacs
No relevant relationships to disclose
V. D. Guardiola Amado
No relevant relationships to disclose
A. M. Flores
No relevant relationships to disclose
A. Ferrell
No relevant relationships to disclose
M. Vulfovich
No relevant relationships to disclose
M. D. Pegram
Consultant or Advisory Role - Bristol-Myers Squibb
P. W. Benedetto
No relevant relationships to disclose
C. M. S. Rocha Lima
No relevant relationships to disclose
J. R. Merchan
Research Funding - Bristol-Myers Squibb; Pfizer